Affordable Access to Prescription Medications Act of 2009

-H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

-S. 1273, National MS and Parkinson's Disease Registries Act, support all provisions. -H.R. 1362, National Neurological Diseases Surveillance System Act, support all provisions. -H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -H.R. 6208, Adult Day Achievement Center Enhancement Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Performance Based Pharmacy Reimbursement/Medication Therapy Management proposal; Postal Service - discussions around 5-day mail delivery; Competitive bidding; HR 1204, Community Pharmacy Fairness Act - antitrust exemption for pharmacies; HR 4489, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act; S. 369, Preserve Access to Affordable Generics Act; S. 1630, Affordable Access to Prescription Medications Act prescription drug copays and formularies; HR 5597, To establish a Medicare patient IVIG access demonstration project; HR 3790, Repeal of DMEPOS competitive bidding program;

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE

Passage of the Arthritis Prevention, Control and Cure Act (S. 984/H.R. 1210) Advocate for increased appropriations for the Centers for Disease Control and Prevetnion and the National Institues of Health Support and Passage of S. 1206, H.R. 3779/S.1630, H.R.3962, H.R. 3799 and H.R.3590 Support and passage of H.R. 3200 and America's Health Future Act of 2009

Client expense: $133,393 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Performance Based Pharmacy Reimbursement/Medication Therapy Management proposal; Postal Service - discussions around 5-day mail delivery; Competitive bidding; HR 1204, Community Pharmacy Fairness Act - antitrust exemption for pharmacies; HR 4489, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act; S. 369, Preserve Access to Affordable Generics Act; S. 1630, Affordable Access to Prescription Medications Act prescription drug copays and formularies; HR 5597, To establish a Medicare patient IVIG access demonstration project; HR 3790, Repeal of DMEPOS competitive bidding program;

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs (cont.) H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch); H.R. 4899, Supplemental Appropriations Act (Obey) generic drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies; S. 3677, Financial Services and General Government Appropriations Act (Durbin) generic drugs PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

Client expense: $2,330,000 · Firm income: Not reported

HR 3248/ S 1283: Lifespan Respite Care Act of 2005; HR 4281: Small Business Health Fairness Act; PL 109-365: Older Americans Act Amendments of 2006; Older Americans Act Reauthorization; Healthcare reform policy; HR 2/PL 111-3: CHIP Reauthorization; HR 3267/S 1760: Healthy Start Reauthorization Act of 2007; HR 1017/S 578: Protecting Children's Health in Schools Act; HR 6111: Tax Relief and Health Care Act of 2006; Combating Autism Act; Expanding the Promise for Individuals with Autism Act; FY 2009 and FY 2010 Labor-HHS-Education Appropriations; PL 110-343: Paul Wellstone and Pete Domenici Mental Health Parity Act; HR 2502: Comparative Effectiveness Research Act of 2009; S 1213: Patient Centered Outcomes Research Act of 2009; HR 3200/S 1679: America's Affordable Health Choices Act of 2009; HR 1708/S 700: Ending the Medicare Disability Waiting Period Act of 2009; S 1630: Affordable Access to Prescription Medications Act of 2009; PL 111-148: The Patient Protection and Affordable Care Act; PL 111-152: Affordable Health Care for America Act; HR 4872: Health Care and Education Reconciliation Act of 2010; HR 4213 American Jobs and Closing Tax Loopholes Act; HR 1347: Concussion Treatment and Care Tools Act of 2010; and PL 111-192: Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act.

Client expense: $57,615 · Firm income: Not reported

Implementation of healthcare reform legislation; generic biologics Executive Branch actions re PL 111-148 and PL 111-152. *Federal Employee Health Benefit Program prescription drugs - HR 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. *Prescription drug co-pays and formularies - S 1630, Affordable Access to Prescription Medications Act of 2009. *Generic drugs - HR 1706, Protecting Consumer Access to Generic Drugs Act of 2009; HR 4899, Supplemental Appropriations Act, 2010; S 369, Preserve Access to Affordable Generics Act; S 3677, Financial Services and General Government Appropriations Act, 2011. *Antitrust exemption for pharmacies - HR 1204, Community Pharmacy Fairness Act of 2009.

Client expense: Not reported · Firm income: $100,000

-H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions. -HR 1586, Education Jobs and Medicaid Assistance Act, support extension of federal Medicaid assistance to states.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

-S. 1273, National MS and Parkinson's Disease Registries Act, support all provisions. -H.R. 1362, National Neurological Diseases Surveillance System Act, support all provisions. -H.R. 5732, Part D Off-label Prescription Parity Act, support all provisions. -HR 1586, Education Jobs and Medicaid Assistance Act, support extension of federal Medicaid assistance to states. -H.R. 6208, Adult Day Achievement Center Enhancement Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Performance Based Pharmacy Reimbursement/Medication Therapy Management proposal; Postal Service - discussions around 5-day mail delivery; competitive bidding; HR 1204, Community Pharmacy Fairness Act - antitrust exemption for pharmacies; HR 3590, Patient Protection and Affordable Care Act - generic biologics; HR 4489, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act; S. 369, Preserve Access to Affordable Generics Act; S. 1630, Affordable Access to Prescription Medications Act prescription drug copays and formularies; HR 5597, To establish a Medicare patient IVIG access demonstration project; HR 3790, Repeal of DMEPOS competitive bidding program; HR 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010 / PL 111-192

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; (cont.) H.R. 3590, Patient Protection and Affordable Care Act (Reid) generic biologics; H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch); H.R. 4899, Supplemental Appropriations Act (Obey) generic drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

Client expense: $2,290,000 · Firm income: Not reported

HR 3248/ S 1283: Lifespan Respite Care Act of 2005; HR 4281: Small Business Health Fairness Act; PL 109-365: Older Americans Act Amendments of 2006; Older Americans Act Reauthorization; Healthcare reform policy; HR 2/PL 111-3: CHIP Reauthorization; HR 3267/S 1760: Healthy Start Reauthorization Act of 2007; HR 1017/S 578: Protecting Children's Health in Schools Act; HR 6111: Tax Relief and Health Care Act of 2006; Combating Autism Act; Expanding the Promise for Individuals with Autism Act; FY 2009 and FY 2010 Labor-HHS-Education Appropriations; PL 110-343: Paul Wellstone and Pete Domenici Mental Health Parity Act; HR 2502: Comparative Effectiveness Research Act of 2009; S 1213: Patient Centered Outcomes Research Act of 2009; HR 3200/S 1679: America's Affordable Health Choices Act of 2009; HR 1708/S 700: Ending the Medicare Disability Waiting Period Act of 2009; S 1630: Affordable Access to Prescription Medications Act of 2009; HR 3590: The Patient Protection and Affordable Care Act; HR 3962: Affordable Health Care for America Act; HR 4872: Health Care and Education Reconciliation Act of 2010; HR 4213 American Jobs and Closing Tax Loopholes Act.

Client expense: $70,970 · Firm income: Not reported

*Antitrust exemption for pharmacies - HR 1204, Community Pharmacy Fairness Act of 2009. *Generic drugs - HR 1706, Protecting Consumer Access to Generic Drugs Act of 2009; HR 4899, Supplemental Appropriations Act, 2010; S 369, Preserve Access to Affordable Generics Act. *Generic biologics - HR 3590, Patient Protection and Affordable Care Act. *Federal Employee Health Benefit Program prescription drugs - HR 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. *Prescription drug co-pays and formularies - S 1630, Affordable Access to Prescription Medications Act of 2009.

Client expense: Not reported · Firm income: $100,000

-S. 1273/H.R. 1362, National MS and Parkinson's Disease Registries Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions. -H.R. 4213, American Jobs and Closing Tax Loopholes Act, support inclusion of COBRA premium assistance extension and of federal Medicaid assistance extension in the form of a temporarily enhanced Federal Medical Assistance Percentage (FMAP). -S. 3548, Extend COBRA Premium Assistance Program Act, support all provisions. -H.R. 3421, Medical Debt Relief Act, support all provisions. -H.R. 3043, Medicare Adult Day Care Services Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

-S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions. -H.R. 4213, American Jobs and Closing Tax Loopholes Act, support inclusion of federal Medicaid assistance extension in the form of a temporarily enhanced Federal Medical Assistance Percentage (FMAP). -H.R. 3043, Medicare Adult Day Care Services Act, support all provisions.

Client expense: $94,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act (Waxman) generic biologics; H.R. 1548, Pathway for Biosimilars Act (Eshoo) generic biologics; (cont.) PHA (Legislative cont.) H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; H.R. 3200, Americas Affordable Health Choices Act (Dingell) generic biologics; H.R. 3590, Patient Protection and Affordable Care Act (Reid) generic biologics; H.R. 3962, Americas Affordable Health Choices Act (Dingell) generic biologics, generic prescription drugs; H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch); S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act (Schumer) generic biologics; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies; S. 1679, Affordable Health Choices Act (Harkin) generic biologics PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

Client expense: $2,700,000 · Firm income: Not reported

Passage of the Arthritis Prevention, Control & Cure Act (S.984/H.R. 1210) Support and Passage of S. 1206, H.R. 3779/S.1630, H.R. 3962, H.R. 3799 & H.R. 3590 Support and Passage of H.R. 3200 and America's Health Future Act of 2009 Advocate for increased appropriations for the Centers for Disease Control & Prevention and the National Institutes of Health

Client expense: $133,393 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1204, Community Pharmacy Fairness Act - antitrust exemption for pharmacies; HR 1427, Promoting Innovation and Access to Life Saving Medicine Act - generic biologics; HR 1548, Pathway for Biosimilars Act - generic biologics; HR 1706, Protecting Consumer Access to Generic Drugs Act - generic drugs; HR 3200, America's Affordable Health Choices Act - medication therapy management, RDS (retiree prescription drug coverage), IVIG (intravenous immune globulin), transparency, data minimg, pharmaceutical benefit manager excise tax, generic biologics; HR 3590, Patient Protection and Affordable Care Act - medication therapy management, RDS (retiree prescription drug coverage), IVIG (intravenous immune globulin), transparency, data mining, pharmaceutical benefit manager excise tax, generic biologics; HR 3962, Affordable Health Care for America Act - medication therapy management, RDS (retiree prescription drug coverage), IVIG (intravenous immune globulin), transparency, data mining, pharmaceutical benefit manager excise tax, generic biologics, generic prescription drugs; HR 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act HR 4872, Health Care and Education Reconciliation Act - medication therapy management, RDS (retiree prescription drug coverage), IVIG (intravenous immune globulin), transparency, data mining, pharmaceutical benefit manager excise tax, generic biologics; S. 369, Preserve Access to Affordable Generics Act - generic drugs; S 726, Promoting Innovation and Access to Life-Saving Medicine Act - generic biologics; S 1630, Affordable Access to Prescription Medications Act - prescription drug co-pays and formularies; S 1679, Affordable Health Choices Act - medication therapy management, RDS (retiree prescription drug coverage), IVIG (intravenous immune globulin), transparency, data mining, pharmaceutical benefit manager excise tax, generic biologics; S 1796, American's Healthy Future Act - medication therapy management, RDS (retiree prescription drug coverage), IVIG (intravenous immune globulin), transparency, data mining, pharmaceutical benefit manager excise tax, generic biologics

HR 3248/ S 1283: Lifespan Respite Care Act of 2005; HR 4281: Small Business Health Fairness Act; PL 109-365: Older Americans Act Amendments of 2006; Older Americans Act Reauthorization; Healthcare reform policy; HR 2/PL 111-3: CHIP Reauthorization; HR 3267/S 1760: Healthy Start Reauthorization Act of 2007; HR 1017/S 578: Protecting Children's Health in Schools Act; HR 6111: Tax Relief and Health Care Act of 2006; Combating Autism Act; Expanding the Promise for Individuals with Autism Act; FY 2009 and FY 2010 Labor-HHS-Education Appropriations; PL 110-343: Paul Wellstone and Pete Domenici Mental Health Parity Act; HR 2502: Comparative Effectiveness Research Act of 2009; S 1213: Patient Centered Outcomes Research Act of 2009; HR 3200/S 1679: America's Affordable Health Choices Act of 2009; HR 1708/S 700: Ending the Medicare Disability Waiting Period Act of 2009; S 1630: Affordable Access to Prescription Medications Act of 2009; HR 3590: The Patient Protection and Affordable Care Act; HR 3962: Affordable Health Care for America Act; HR 4872: Health Care and Education Reconciliation Act of 2010.

Client expense: $46,308 · Firm income: Not reported

-S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions. -H.R. 3590, Patient Protection and Affordable Care Act, support provisions improving access to and quality of care for those living with MS. -H.R. 4872, Health Care and Education Reconciliation Act, support provisions improving access to and quality of care for those living with MS.

Client expense: $294,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

-S. 1273/H.R. 1362, National MS and Parkinson's Disease Registries Act, support all provisions. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions. -H.R. 3590, Patient Protection and Affordable Care Act, support provisions improving access to and quality of care for those living with MS. -H.R. 4872, Health Care and Education Reconciliation Act, support provisions improving access to and quality of care for those living with MS. -H.R. 3421, Medical Debt Relief Act, support all provisions. -H.R. 2084, Prevention, Awareness, and Research of Autoimmune Diseases Act, support all provisions.

Client expense: $294,501 · Firm income: Not reported

Government targets: Administration on Aging, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

Medicare/Part B Premium Hold Harmless. H.R. 3631: Provisions extending the current "hold harmless" policy to all Medicare enrollees to ensure 2010 Part B monthly premiums remain at the current rate. Comprehensive Health Care Reform. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590: provisions related to reducing Medicare Advantage plan payments, reducing the coverage gap in Part D, requiring wealthier Medicare beneficiaries to pay a greater share of the cost of their premiums under Medicare Parts B and D, permitting the Department of Health and Human Services to negotiate drug prices for the Part D program, simplifying plan benefit designs under Part C, expanding benefits for low-income beneficiaries under the Medicare Savings Programs and the Part D Low-Income Subsidy (LIS), improving the process for reassigning LIS beneficiaries to new plans, expanding coverage of prevention services establishing a Medicare Commission, providing expanded Medicaid coverage for home and community-based services, expanding Medicaid coverage of attendant and other home services and supports, establishing a new national insurance program for long-term supports and services, authorizing funding to provide language services to limited English proficiency beneficiaries, authorizing the collection of data regarding disparities in the provision of care, providing safeguards and subsidies to assure affordability of health coverage for seniors, preserving state benefit laws and requirements, reducing permitted age rating ratio for insurance premiums, inclusion of patient-centered quality reporting requirements for providers, creating new claims reviews processes and provider certification, requiring reporting by practitioners of gifts received from pharmaceutical and medical device manufacturers. Medicare/Commission. P.L. 111-148, P.L. 111-152, H.R. 4872: creating an independent commission authorized to establish Medicare payment and policy designed to reduce Medicare spending growth. Medicare/Prescription Drug Plan. S. 330, H.R. 684: authorizing the establishment of a Medicare-operated prescription drug plan; S. 266: authorizing the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Part D Generics. S. 75: requiring the use of generics where available unless the brand name drug is determined to be medically necessary. Medicare/Part D cost-sharing. S. 1630: establishing limits on required beneficiary cost-sharing under Part D drug plans. Medicare/Part D dual eligibles. P.L. 111-148, P.L. 111-152, H.R. 4872, S. 1634: removing enrollment barriers for low-income beneficiaries and establishing a Medicare-operated prescription drug plan. Medicare/Combating Waste, Fraud, Abuse. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 27: relating to provisions to combat waste, fraud, and abuse within Medicare; H.R. 203: increasing civil and criminal penalties for acts involving fraud and abuse and increasing the surety bond amount for suppliers of durable medical equipment. Medicare/Therapy Caps. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 43, S. 46: repealing or extending exceptions to outpatient rehabilitation therapy caps. Medicare/Private Contracts. H.R. 164: prohibiting denial of Social Security benefits to persons who elect not to participate in Medicare. Medicare/Hearing Coverage. H.R. 504: authorizing coverage of hearing aids and auditory rehabilitation services under Medicare Part B. Medicare/Dental Coverage. H.R. 870: authorizing coverage under Part B for medically necessary dental procedures. Medicare/Rural Improvements. H.R. 902/S. 382: provision authorizing improvements to services provided to beneficiaries residing in rural areas. Medicare/Shingles Vaccine. H.R. 1038: extending Part B coverage to the shingles vaccine. Medicare/Home Health. H.R. 1094: authorizing home health care agencies to assign the most appropriate skilled service to make the initial assessment visit under a Medicare home health plan of care for rehabilitation services. Medicare/Health Care Vouchers. H.R. 1118: authorizing Medicare-eligible seniors to elect to receive vouchers for a health savings account, premiums for a high deductible health insurance plan, or both, in lieu of regular Medicare benefits and suspending Medicare late enrollment penalties between ages 65 and 70. Medicare/Skilled Nursing Facilities. H.R. 1125, S. 647: provisions related to requiring the reporting of expenditures for nursing services at skilled nursing facilities and requiring disclosure of corporate ownership. Medicare/Prevention. H.R. 1213: provisions authorizing ultrasound screening for abdominal aortic aneurysms to at-risk Medicare beneficiaries between the ages of 65 and 75 without the requirement of a prior initial preventive physical examination; H.R. 1894, S. 769: expanding access to bone mass measurement benefits under Part B. Medicare/Part B Drug Payments. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 1392: relating to appropriate Part B payment amounts for drugs and biologicals. Medicare/Low Income Prescription Drug Benefits. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, H.R. 1407, S. 534: authorizing a reduction in cost-sharing under Part D for non-institutionalized, full-benefit dual eligible individuals. Medicare/Disability Benefits. S. 700, H.R. 1708, H.R. 2881: phasing-out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Prescription Drugs for kidney transplants. H.R. 1458, S. 565: provision related to continued coverage for immunosuppressive drugs furnished to beneficiaries that have received kidney transplants and whose entitlement to coverage would otherwise expire. Medicare/Intravenous Drugs. H.R. 1765, S.701: relating to the payment for intravenous immune globulin (IVIG) for the treatment of primary immune deficiency diseases in a patient's home and for certain disposable pumps as durable medical equipment in place of non-disposable pumps. Medicare/Home Infusion Therapy. H.R. 574, S.254: extending Medicare coverage to home infusion therapy. Medicare/Physical Therapy Services. H.R. 1829: authorizing physical therapists to evaluate and treat Medicare beneficiaries without physician referral. Medicare/Part D Premiums. H.R. 1832: limiting Part D premium increases to no more than the Social Security cost-of-living adjustment and requiring the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Cancer Hospice and Palliative Care. H.R. 1844: provisions authorizing coverage of comprehensive cancer care planning, establishing a Medicare hospice care demonstration, and authorizing grant programs for cancer palliative care and symptom management, provider education, and related research. Medicare/Hospice and Advanced Care Planning. S. 1150, H.R. 2911: provisions related to changing hospice payments and providing advance care planning resources. Medicare/Physician-Manufacturer Transparency. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 301: increasing the transparency of the relationship between physicians and the manufacturers of drugs, devices, biologicals, and medical supplies. Medicare/Care Coordination Services. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 1131, H.R. 2560: provisions establishing pilot care coordination programs. Medicaid/Home and Community-based Long Term Care. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 434, S.1257, H.R. 28552: provisions to remove barriers to providing home and community-based services including providing a state option to provide home and community-based services to individuals for whom such services are likely to prevent, delay, or decrease the likelihood of an individual's need for institutionalized care and authorizing the implementation of assistance grants for states electing to provide home and community-based services under Medicaid; provisions to provide a single point of entry to long term services; provisions to support nursing home diversion programs. Medicaid/Community-based Attendant Services and Supports. P.L. 111-148, P.L. 111-152, H.R. 4872, H.R. 3590, S. 683, H.R. 1670: authorizing coverage of community-based attendant services and supports under Medicaid, increasing funding and establishing a demonstration program for beneficiaries dually eligible for Medicare and Medicaid. P.L. 110-275, P.L. 108-173: implementation of regulations and guidance relating to beneficiary eligibility, enrollment, and effectiveness of exceptions and appeals processes under Medicare Parts C and D.

H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009 H.R. 574 - Medicare Home Infusion Therapy Coverage Act of 2009 S. 75 - Generics First Act of 2009 (Part D) H.R. 2502 - Comparative Effectiveness Research Act H.R. 3200 - America's Affordable Heath Choices Act of 2009. H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009 S. 1630 - Affordable Access to Prescription Medicine Act of 2009 S. 1679 - Affordable Heath Choices Act of 2009 Medicare Prescription Drug Benefit Implementation Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Medicare Secondary Payer Guidance

Client expense: $6,200,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)

H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009 H.R. 574 - Medicare Home Infusion Therapy Coverage Act of 2009 S. 75 - Generics First Act of 2009 (Part D) H.R. 2502 - Comparative Effectiveness Research Act H.R. 3200 - America's Affordable Heath Choices Act of 2009. H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009 S. 1630 - Affordable Access to Prescription Medicine Act of 2009 S. 1679 - Affordable Heath Choices Act of 2009 Medicare Prescription Drug Benefit Implementation Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Medicare Secondary Payer Guidance

Client expense: $5,490,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)

H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009 H.R. 574 - Medicare Home Infusion Therapy Coverage Act of 2009 S. 75 - Generics First Act of 2009 (Part D) H.R. 2502 - Comparative Effectiveness Research Act H.R. 3200 - America's Affordable Heath Choices Act of 2009. H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009 S. 1630 - Affordable Access to Prescription Medicine Act of 2009 S. 1679 - Affordable Heath Choices Act of 2009 Medicare Prescription Drug Benefit Implementation Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Medicare Secondary Payer Guidance

Client expense: $5,590,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act (Waxman) generic biologics; H.R. 1548, Pathway for Biosimilars Act (Eshoo) generic biologics (cont.) H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; H.R. 3200, Americas Affordable Health Choices Act (Dingell) generic biologics; H.R. 3590, Patient Protection and Affordable Care Act (Reid) generic biologics; H.R. 3962, Americas Affordable Health Choices Act (Dingell) generic biologics, generic prescription drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act (Schumer) generic biologics; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies; S. 1679, Affordable Health Choices Act (Harkin) generic biologics PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

Client expense: $2,540,000 · Firm income: Not reported

H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009 H.R. 574 - Medicare Home Infusion Therapy Coverage Act of 2009 S. 75 - Generics First Act of 2009 (Part D) H.R. 2502 - Comparative Effectiveness Research Act H.R. 3200 - America's Affordable Heath Choices Act of 2009. H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009 S. 1630 - Affordable Access to Prescription Medicine Act of 2009 S. 1679 - Affordable Heath Choices Act of 2009 Medicare Prescription Drug Benefit Implementation Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Medicare Secondary Payer Guidance

Client expense: $5,590,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)

HR 3248/ S 1283: Lifespan Respite Care Act of 2005; HR 4281: Small Business Health Fairness Act; PL 109-365: Older Americans Act Amendments of 2006; S 845: Safety of Seniors Act of 2007; Healthcare reform policy; HR 2/PL 111-3: CHIP Reauthorization; HR 3267/S 1760: Healthy Start Reauthorization Act of 2007; HR 1017/S 578: Protecting Children's Health in Schools Act; HR 6111: Tax Relief and Health Care Act of 2006; Combating Autism Act; Expanding the Promise for Individuals with Autism Act; FY 2009 and FY 2010 Labor-HHS-Education Appropriations; PL 110-343: Paul Wellstone and Pete Domenici Mental Health Parity Act; HR 2502: Comparative Effectiveness Research Act of 2009; S 1213: Patient Centered Outcomes Research Act of 2009; HR 3200/S 1679: America's Affordable Health Choices Act of 2009; HR 1708/S 700: Ending the Medicare Disability Waiting Period Act of 2009; S 1630: Affordable Access to Prescription Medications Act of 2009; HR 3590: The Patient Protection and Affordable Care Act; HR 3962: Affordable Health Care for America Act.

Client expense: $55,786 · Firm income: Not reported

Passage of the Arthritis Prevention, Control & Cure Act (S. 984/H.R. 1210) Support and Passage of S. 1206, H.R. 3779/S.1630, H.R. 3962, & H.R. 3590 Support and passage of H.R. 3200 and America's Health Future Act of 2009 Advocate for increased appropriations for the Centers for Disease Control & Prevention and the National Institutes of Health

Client expense: $133,393 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

-S. 1273/H.R. 1362, National MS and Parkinson's Disease Registries Act, support all provisions. -H.R. 3200, America's Affordable Health Choices Act, support provisions improving access to and quality of care for those living with MS. -H.R. 3962, Affordable Health Care for America Act, support provisions improving access to and quality of care for those living with MS. -H.R. 3590, The Patient Protection and Affordable Care Act, support provisions improving access to and quality of care for those living with MS. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $87,273 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

-H.R. 3200, America's Affordable Health Choices Act, support provisions improving access to and quality of care for those living with MS. -H.R. 3962, Affordable Health Care for America Act, support provisions improving access to and quality of care for those living with MS. -H.R. 3590, The Patient Protection and Affordable Care Act, support provisions improving access to and quality of care for those living with MS. -S. 1630/H.R. 3799, Affordable Access to Prescription Medications Act, support all provisions.

Client expense: $87,273 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare/Part B Premium Hold Harmless. H.R. 3631: Provisions extending the current "hold harmless" policy to all Medicare enrollees to ensure 2010 Part B monthly premiums remain at the current rate. Comprehensive Health Care Reform. H.R. 3590, H.R. 3962, H.R. 3200, S. 1679: provisions related to reducing Medicare Advantage plan payments, reducing the coverage gap in Part D, requiring wealthier Medicare beneficiaries to pay a greater share of the cost of their premiums under Medicare Parts B and D, permitting the Department of Health and Human Services to negotiate drug prices for the Part D program, simplifying plan benefit designs under Part C, expanding benefits for low-income beneficiaries under the Medicare Savings Programs and the Part D Low-Income Subsidy (LIS), improving the process for reassigning LIS beneficiaries to new plans, expanding coverage of prevention services establishing a Medicare Commission, providing expanded Medicaid coverage for home and community-based services, expanding Medicaid coverage of attendant and other home services and supports, establishing a new national insurance program for long-term supports and services, authorizing funding to provide language services to limited English proficiency beneficiaries, authorizing the collection of data regarding disparities in the provision of care, providing safeguards and subsidies to assure affordability of health coverage for seniors, preserving state benefit laws and requirements, reducing permitted age rating ratio for insurance premiums, inclusion of patient-centered quality reporting requirements for providers, creating new claims reviews processes and provider certification, requiring reporting by practitioners of gifts received from pharmaceutical and medical device manufacturers. Medicare/Commission. S. 1110 and S. 1380: authorizing an enhanced MedPAC as an executive branch commission with authority to implement Medicare payment and policy designed to reduce Medicare spending growth. Medicare/Prescription Drug Plan. S. 330/H.R. 684: authorizing the establishment of a Medicare-operated prescription drug plan; S. 266: authorizing the Secretary of Health and Human Services to negotiate lower prescription drug prices and to use the savings to reduce the coverage gap. Medicare/Part D Generics. S. 75: requiring the use of generics where available unless the brand name drug is determined to be medically necessary. Medicare/Part D cost-sharing. S. 1630: establishing limits on required beneficiary cost-sharing under Part D drug plans. Medicare/Part D dual eligibles. S. 1634: removing enrollment barriers for low-income beneficiaries and establishing a Medicare-operated prescription drug plan. Medicare/Combating Waste, Fraud, Abuse. H.R. 27: relating to additional provisions to combat waste, fraud, and abuse within Medicare; H.R. 203: increasing civil and criminal penalties for acts involving fraud and abuse and increasing the surety bond amount for suppliers of durable medical equipment. Medicare/Therapy Caps. H.R. 43/S. 46: repealing outpatient rehabilitation therapy caps. Medicare/Private Contracts. H.R. 164: prohibiting denial of Social Security benefits to persons who elect not to participate in Medicare. Medicare/Hearing Coverage. H.R. 504: authorizing coverage of hearing aids and auditory rehabilitation services under Medicare Part B. Medicare/Dental Coverage. H.R. 870: authoring coverage under Part B for medically necessary dental procedures. Medicare/Rural Improvements. H.R. 902/S. 382: provision authorizing improvements to services provided to beneficiaries residing in rural areas. Medicare/Shingles Vaccine. H.R. 1038: extending Part B coverage to the shingles vaccine. Medicare/Home Health. H.R. 1094: authorizing home health care agencies to assign the most appropriate skilled service to make the initial assessment visit under a Medicare home health plan of care for rehabilitation services. Medicare/Health Care Vouchers. H.R. 1118: authorizing Medicare-eligible seniors to elect to receive vouchers for a health savings account, premiums for a high deductible health insurance plan, or both, in lieu of regular Medicare benefits and suspending Medicare late enrollment penalties between ages 65 and 70. Medicare/Skilled Nursing Facilities. H.R. 1125, S. 647: provisions related to requiring the reporting of expenditures for nursing services at skilled nursing facilities and requiring disclosure of corporate ownership. Medicare/Prevention. H.R. 1213: provisions authorizing ultrasound screening for abdominal aortic aneurysms to at-risk Medicare beneficiaries between the ages of 65 and 75 without the requirement of a prior initial preventive physical examination; H.R. 1894/S. 769: expanding access to bone mass measurement benefits under Part B. Medicare/Part B Drug Payments. H.R. 1392: relating to appropriate Part B payment amounts for drugs and biologicals. Medicare/Low Income Prescription Drug Benefits. H.R. 1407/S. 534: authorizing a reduction in cost-sharing under Part D for non-institutionalized, full-benefit dual eligible individuals. Medicare/Disability Benefits. S. 700/H.R. 1708, H.R. 2881: phasing-out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Prescription Drugs for kidney transplants. H.R. 1458/S. 565: provision related to continued coverage for immunosuppressive drugs furnished beneficiaries that have received kidney transplants and whose entitlement to coverage would otherwise expire. Medicare/Intravenous Drugs. H.R. 1765/S.701: relating to the payment for intravenous immune globulin (IVIG) for the treatment of primary immune deficiency diseases in a patient's home and for certain disposable pumps as durable medical equipment in place of non-disposable pumps. Medicare/Home Infusion Therapy. H.R. 574/S.254: extending Medicare coverage to home infusion therapy. Medicare/Physical Therapy Services. H.R. 1829: authorizing physical therapists to evaluate and treat Medicare beneficiaries without physician referral. Medicare/Part D Premiums. H.R. 1832: limiting Part D premium increases to no more than the Social Security cost-of-living adjustment and requiring the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Cancer Hospice and Palliative Care. H.R. 1844: provisions authorizing coverage of comprehensive cancer care planning, establishing a Medicare hospice care demonstration, and authorizing grant programs for cancer palliative care and symptom management, provider education, and related research. Medicare/Hospice and Advanced Care Planning. S. 1150, H.R. 2911: provisions related to changing hospice payments and providing advance care planning resources. Medicare/Physician-Manufacturer Transparency. S. 301: increasing the transparency of the relationship between physicians and the manufacturers of drugs, devices, biologicals, and medical supplies. Medicare/Care Coordination Services. S. 1131, H.R. 2560: provisions establishing pilot care coordination program.

H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009 H.R. 574 - Medicare Home Infusion Therapy Coverage Act of 2009 S. 75 - Generics First Act of 2009 (Part D) H.R. 2502 - Comparative Effectiveness Research Act H.R. 3200 - America's Affordable Heath Choices Act of 2009. H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009 S. 1630 - Affordable Access to Prescription Medicine Act of 2009 S. 1679 - Affordable Heath Choices Act of 2009 Medicare Prescription Drug Benefit Implementation Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Medicare Secondary Payer Guidance

Client expense: $5,420,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, Veterans Affairs, Dept of (VA)

H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act (Waxman) generic biologics (cont.) PHA (cont.) H.R. 1548, Pathway for Biosimilars Act (Eshoo) generic biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; H.R. 3200, Americas Affordable Health Choices Act (Dingell) generic biologics; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act (Schumer) generic biologics; S. 1630, Affordable Access to Prescription Medications Act (Rockefeller) prescription drug co-pays and formularies; S. 1679, Affordable Health Choices Act (Harkin) generic biologics PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.

Client expense: $2,410,000 · Firm income: Not reported

FDA Drug Approval regulations, coverage of off label medications, reducing out of pocket costs, S. 1630, health care reform, CDC National Lupus Patient Registry, Peer Reviewed Medical Research funding through DoD, Comparative Effectiveness research at AHRQ and IOM

Client expense: $11,636 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Medicare/Part B Premium Hold Harmless. H.R. 3631: Provisions extending the current "hold harmless" policy to all Medicare enrollees to ensure 2010 Part B monthly premiums remain at the current rate. Comprehensive Health Care Reform. H.R. 3200, S. 1679, Senate Finance Committee Mark of Americas Healthy Futures Act: provisions related to reducing Medicare Advantage plan payments, reducing the coverage gap in Part D, requiring wealthier Medicare beneficiaries to pay a greater share of the cost of their premiums under Medicare Part D, reducing the Part A deductible, establishing an out-of-pocket maximum under Medicare, establishing a voluntary comprehensive benefit option under Medicare, authorizing a Medicare-operated Part D drug plan, permitting the Department of Health and Human Services to negotiate drug prices for the Part D program, simplifying plan benefit designs under Parts D and C, expanding benefits for low-income beneficiaries under the Medicare Savings Programs and the Part D Low-Income Subsidy (LIS), improving the process for reassigning LIS beneficiaries to new plans, expanding coverage of prevention services, integrating mental health services in primary care and community settings, eliminating the 45 percent funding trigger provision, establishing a Medicare Commission, providing Medicaid coverage for home and community-based services, establishing a new national insurance program for long-term supports and services, authorizing funding to provide language services to limited English proficiency beneficiaries, authorizing the collection of data regarding disparities in the provision of care, providing safeguards and subsidies to assure affordability of health coverage for seniors, preserving state benefit laws and requirements, reducing permitted age rating ratio and clarifying the Medicare Secondary Payer statute. Medicare/Commission. S. 1110 and S. 1380: authorizing an enhanced MedPAC as an executive branch commission with authority to implement Medicare payment and policy designed to reduce Medicare spending growth. Medicare/Prescription Drug Plan. S. 330/H.R. 684: authorizing the establishment of a Medicare-operated prescription drug plan; S. 266: authorizing the Secretary of Health and Human Services to negotiate lower prescription drug prices and to use the savings to reduce the coverage gap. Medicare/Part D Generics. S. 75: requiring the use of generics where available unless the brand name drug is determined to be medically necessary. Medicare/Part D cost-sharing. S. 1630: establishing limits on required beneficiary cost-sharing under Part D drug plans. Medicare/Part D dual eligibles. S. 1634: removing enrollment barriers for low-income beneficiaries and establishing a Medicare-operated prescription drug plan. Medicare/Combating Waste, Fraud, Abuse. H.R. 27: relating to additional provisions to combat waste, fraud, and abuse within Medicare; H.R. 203: increasing civil and criminal penalties for acts involving fraud and abuse and increasing the surety bond amount for suppliers of durable medical equipment. Medicare/Therapy Caps. H.R. 43/S. 46: repealing outpatient rehabilitation therapy caps. Medicare/Private Contracts. H.R. 164: prohibiting denial of Social Security benefits to persons who elect not to participate in Medicare. Medicare/Hearing Coverage. H.R. 504: authorizing coverage of hearing aids and auditory rehabilitation services under Medicare Part B. Medicare/Dental Coverage. H.R. 870: authoring coverage under Part B for medically necessary dental procedures. Medicare/Rural Improvements. H.R. 902/S. 382: provision authorizing improvements to services provided to beneficiaries residing in rural areas. Medicare/Shingles Vaccine. H.R. 1038: extending Part B coverage to the shingles vaccine. Medicare/Home Health. H.R. 1094: authorizing home health care agencies to assign the most appropriate skilled service to make the initial assessment visit under a Medicare home health plan of care for rehabilitation services. Medicare/Health Care Vouchers. H.R. 1118: authorizing Medicare-eligible seniors to elect to receive vouchers for a health savings account, premiums for a high deductible health insurance plan, or both, in lieu of regular Medicare benefits and suspending Medicare late enrollment penalties between ages 65 and 70. Medicare/Skilled Nursing Facilities. H.R. 1125, S. 647: provisions related to requiring the reporting of expenditures for nursing services at skilled nursing facilities and requiring disclosure of corporate ownership. Medicare/Prevention. H.R. 1213: provisions authorizing ultrasound screening for abdominal aortic aneurysms to at-risk Medicare beneficiaries between the ages of 65 and 75 without the requirement of a prior initial preventive physical examination; H.R. 1894/S. 769: expanding access to bone mass measurement benefits under Part B. Medicare/Part B Drug Payments. H.R. 1392: relating to appropriate Part B payment amounts for drugs and biologicals. Medicare/Low Income Prescription Drug Benefits. H.R. 1407/S. 534: authorizing a reduction in cost-sharing under Part D for non-institutionalized, full-benefit dual eligible individuals. Medicare/Disability Benefits. S. 700/H.R. 1708, H.R. 2881: phasing-out the 24-month waiting period for disabled individuals to become eligible for Medicare benefits and eliminating the waiting period for individuals with life-threatening conditions. Medicare/Prescription Drugs for kidney transplants. H.R. 1458/S. 565: provision related to continued coverage for immunosuppressive drugs furnished beneficiaries that have received kidney transplants and whose entitlement to coverage would otherwise expire. Medicare/Intravenous Drugs. H.R. 1765/S.701: relating to the payment for intravenous immune globulin (IVIG) for the treatment of primary immune deficiency diseases in a patient's home and for certain disposable pumps as durable medical equipment in place of non-disposable pumps. Medicare/Home Infusion Therapy. H.R. 574/S.254: extending Medicare coverage to home infusion therapy. Medicare/Physical Therapy Services. H.R. 1829: authorizing physical therapists to evaluate and treat Medicare beneficiaries without physician referral. Medicare/Part D Premiums. H.R. 1832: limiting Part D premium increases to no more than the Social Security cost-of-living adjustment and requiring the Secretary of Health and Human Services to negotiate lower prescription drug prices. Medicare/Cancer Hospice and Palliative Care. H.R. 1844: provisions authorizing coverage of comprehensive cancer care planning, establishing a Medicare hospice care demonstration, and authorizing grant programs for cancer palliative care and symptom management, provider education, and related research. Medicare/Hospice and Advanced Care Planning. S. 1150, H.R. 2911: provisions related to changing hospice payments and providing advance care planning resources. Medicare/Physician-Manufacturer Transparency. S. 301: increasing the transparency of the relationship between physicians and the manufacturers of drugs, devices, biologicals, and medical supplies. Medicare/Care Coordination Services. S. 1131, H.R. 2560: provisions establishing pilot care coordination program. Medicaid/Home and Community-based Long Term Care. S. 434, S.1257, H.R. 28552: provisions to remove barriers to providing home and community-based services including providing a state option to provide home and community-based services to individuals for whom such services are likely to prevent, delay, or decrease the likelihood of an individual's need for institutionalized care and authorizing the implementation of assistance grants for states electing to provide home and community-based services under Medicaid; provisions to provide a single point of entry to long term services; provisions to support nursing home diversion programs. Medicaid/Community-based Attendant Services and Supports. S. 683, H.R. 1670: authorizing coverage of community-based attendant services and supports under Medicaid, increasing funding and establishing a demonstration program for beneficiaries dually eligible for Medicare and Medicaid.

National MS and Parkinson's Disease Registry Act (S. 1273/H.R. 1362); America's Affordable Health Choices Act (H.R. 3200); Promoting Innovation and Access to Lifesaving Medicine Act (H.R. 1427); Affordable Access to Prescription Medications Act (S. 1630/H.R. 3799)

Client expense: $87,273 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Social Security Administration (SSA)

HR 3248/ S1283: Lifespan Respite Care Act of 2005; HR 4281: Small Business Health Fairness Act; PL 109-365: Older Americans Act Amendments of 2006; S 845: Safety of Seniors Act of 2007; Health care reform policy; HR 2/PL 111-3: CHIP reauthorization; HR 3267/S 1760: Health Start Reauthorization Act of 2007; HR 1017/S 578: Protecting Children's Health in Schools Act; HR 6111: Tax Relief and Health Care Act of 2006; Combating Autism Act; Expanding the Promise for Individuals with Autism Act; FY 2009 and FY 2010 Labor-HHS-Education Appropriations; PL 110-343: Paul Wellstone and Pete Domenici Mental Health Parity Act; HR 2502: Comparative Effectiveness Research Act of 2009; S 1213: Patient Centered Outcomes Research Act of 2009; HR 3200/S 1679: America's Affordable Health Choices Act of 2009; HR 1708/S 700: Ending the Medicare Disability Waiting Period Act of 2009; S 1630: Affordable and Access to Prescription Medications Act of 2009.

Client expense: $55,960 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Education, Dept of, Equal Employment Opportunity Commission (EEOC), Federal Communications Commission (FCC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Council on Disability, SENATE, Transportation, Dept of (DOT), U.S. Architectural & Transportation Barriers Compliance Board (ACCESS), Veterans Affairs, Dept of (VA), White House Office

HR 2801 Izembek Enhancement Act S 1630 Izembek Enhancement Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE